Abstract: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin.

Abstract: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds.

Abstract: Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.

Abstract: The invention provides pharmaceutical compositions comprising TGF-? superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF-? superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-? superfamily members in a pharmaceutical composition. Uses of the pharmaceutical compositions are also described, particularly with reference to wound healing and fibrosis. Furthermore, the invention discloses medicaments for the prevention or reduction of injection pain.

Abstract: The invention relates to the use of TGF-?3, or agents having TGF-?3 activity, to promote epithelial regeneration. Methods of manufacturing medicaments, and methods of promoting epithelial regeneration are both provided. In particular, the medicaments and methods of treatment of the invention are applicable to the promotion of epithelial regeneration in healthy patients, and/or in acute wounds.

Abstract: The invention provides pharmaceutical compositions comprising TGF-? superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF-? superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-? superfamily members in a pharmaceutical composition. Uses of the pharmaceutical compositions are also described, particularly with reference to wound healing and fibrosis. Furthermore, the invention discloses medicaments for the prevention or reduction of injection pain.